Research · 8 min read
Compounded vs Brand GLP-1s: What the Difference Actually Means for You
The real distinction is not potency or quality in the abstract. It is that one product was reviewed and approved by the FDA and the other was not, and everything that follows from that is about accountability.
Key takeaways
- Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- 503A pharmacies and 503B outsourcing facilities are different legal categories with different oversight — ask which applies.
- Compounding of these ingredients was largely shortage-driven; check FDA's shortage database for the current status.
- FDA has warned that salt forms such as semaglutide sodium are different active ingredients from approved semaglutide.
- Vial-and-syringe presentation shifts a measurement step to the patient that a labeled pen removes.
The legal difference, stated exactly
A brand GLP-1 is an FDA-approved drug product. The agency has reviewed its manufacturing, its evidence of safety and effectiveness for the labeled use, and the labeling itself. Every unit is made under the conditions in that approved application.
A compounded preparation is made by a pharmacy or an outsourcing facility to fill a need the approved product is not filling. Compounded drugs are not FDA-approved. The agency does not review them for safety, effectiveness, or quality before they reach a patient, and it says so directly. That is not an accusation against any particular pharmacy. It is a description of what the category is.
So this is not compounded versus brand as two grades of the same thing. On one side is a reviewed product with a manufacturer standing behind it. On the other is a preparation whose quality depends on the practices of the specific facility that made it, with far less external verification in between.
503A and 503B are not the same thing, and the difference matters
Compounding in the United States happens in two distinct legal categories, and the terms show up on pharmacy websites without much explanation.
A traditional compounding pharmacy operating under section 503A compounds for an individual patient pursuant to a prescription. It is licensed and inspected primarily by its state board of pharmacy.
An outsourcing facility under section 503B registers with the FDA and can produce batches without patient-specific prescriptions. It is subject to federal inspection and to current good manufacturing practice requirements. That is a meaningfully higher bar for manufacturing oversight, though it still does not make the product FDA-approved.
If you are being offered a compounded preparation, ask which category the pharmacy operates in. It is a fair and answerable question. A program that cannot or will not name the pharmacy at all has told you something useful.
Why compounded GLP-1s became common, and why the ground shifted
The legal opening was shortage. When an approved drug is listed on FDA's drug shortage list, compounders have latitude they do not otherwise have to prepare a version of it, because the alternative for patients is nothing. Demand for these medications outran supply for an extended period, and a large compounded market formed in that gap.
That situation changed once FDA determined the shortages of these ingredients were resolved. Resolving a shortage removes the basis on which much of that compounding was permitted, and it triggered a wind-down with deadlines and litigation attached. The details have continued to move. No status or date is printed here for you to rely on months from now.
Do this instead. Check the current status in FDA's own drug shortage database before assuming anything about what is legitimately available. Then ask any program offering a compounded product on what basis it is compounding today. That question has a clear answer, and a vague response to it is itself information.
Not everything sold as semaglutide is semaglutide
FDA has warned specifically about salt forms of semaglutide — variants such as semaglutide sodium or semaglutide acetate. These are different active ingredients from the semaglutide in the approved products. This became a real problem in the market rather than a theoretical one.
Combination preparations that mix a GLP-1 with other substances are likewise not approved products, and adding an ingredient does not make a formulation better validated. Marketing language about enhanced or personalized formulas describes a decision the seller made, not an evidence base.
The concrete step for a buyer is dull and effective. Read the active ingredient exactly as printed on the label of what you receive, and ask what else is in the vial. If the string on the label is not the ingredient you believe you are taking, that is worth stopping over.
What differs in your hands, week to week
Presentation is the difference people feel first. Brand products are supplied as pens with the manufacturer's Instructions for Use and labeled increments. Compounded preparations typically arrive as a vial with a syringe, where the person injecting is measuring a volume — often described in units — from a concentration the pharmacy chose. That shifts a measurement responsibility onto the patient that the approved product's design removes, and it is a well-recognized source of error.
Documentation differs too. There is generally no manufacturer's Instructions for Use leaflet and no manufacturer prescribing information for a compounded preparation. The instructions come from the pharmacy and the prescriber, so find out in advance who answers a question about the product itself.
Continuity is the third difference. What a compounder can legally supply has already changed once, and a supply that depends on a regulatory posture can change again. If continuity over a long treatment period matters to you, weigh that at the start rather than discovering it mid-course.
There is also a difference in recourse. With an approved product there is a manufacturer, a published label, an established adverse-event reporting path, and manufacturer support programs. With a compounded preparation, the party standing behind the product is the pharmacy that made it. Who you call if something goes wrong has a different answer.
Questions worth asking before you buy either one
Which pharmacy actually prepares and ships this, by name, and is it operating under 503A or 503B? What exactly is the active ingredient as it will appear on the label, and is anything else in the vial? What presentation arrives, and what written instructions come with it? Who do I contact about a reaction or a product question — the prescriber, or the pharmacy? What happens to my treatment if this pharmacy can no longer supply it?
For a brand product the useful questions are different. Which brand and indication is being prescribed? Does the program handle prior authorization? Are you being routed to your own pharmacy benefit, or to a cash-pay channel?
In both cases, a program that answers these plainly is telling you something about how it operates, and one that deflects is telling you something too. Those answers, not the ranking on any comparison page, are what should decide it.
Frequently asked questions
Is a compounded GLP-1 the same drug as the brand version?
It may contain the same active ingredient, but it is not the same product. The brand product is FDA-approved, meaning the agency reviewed its manufacturing and its evidence of safety and effectiveness. A compounded preparation is not FDA-approved, and FDA does not review it for safety, effectiveness, or quality before it reaches a patient. Its quality depends on the practices of the specific facility that prepared it. FDA has also warned that some products sold under the semaglutide name have used salt forms that are different active ingredients entirely.
Are compounded GLP-1s still legal to obtain?
What compounders may legally prepare has changed since FDA determined that the shortages of these ingredients were resolved, and the picture has continued to develop. No status is stated here, because that kind of claim goes stale without anyone noticing. Check FDA's drug shortage database for the current position, and ask any program offering a compounded product on what legal basis it is compounding today.
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy compounds for individual patients against a prescription and is overseen primarily by its state board of pharmacy. A 503B outsourcing facility registers with FDA, may produce batches without patient-specific prescriptions, and is subject to federal inspection and current good manufacturing practice requirements. The 503B category carries more manufacturing oversight, though products from neither category are FDA-approved. Which category a given program uses is a reasonable question to ask before ordering.
Why does the vial-and-syringe format matter?
Because it moves a measurement step to you. An approved pen delivers labeled increments by design. With a vial, you are drawing a volume from a concentration the pharmacy selected, usually described in units, and errors in that step are a recognized risk. It also means the written instructions come from the pharmacy and prescriber rather than a manufacturer's Instructions for Use leaflet. Confirm who to ask when a question about administration comes up.
Does a personalized or combination formula offer any advantage?
Adding ingredients to a compounded preparation is a decision the seller made, not a validated improvement. Combination formulations are not FDA-approved products, and there is no approval process behind the specific mixture being offered. If a program markets an enhanced formula, ask what exactly is in it and why. Weigh the answer knowing that no regulator reviewed the combination.